Sanofi says Gaucher pill studies meet goals

PARIS Fri Feb 15, 2013 10:44pm IST

Chris Viehbacher, Chief Executive Officer of Sanofi, poses for the media before the company's 2012 annual results presentation in Paris February 7, 2013. REUTERS/Jacky Naegelen

Chris Viehbacher, Chief Executive Officer of Sanofi, poses for the media before the company's 2012 annual results presentation in Paris February 7, 2013.

Credit: Reuters/Jacky Naegelen

Related Topics

Stocks

   

PARIS (Reuters) - Sanofi said its experimental pill for Gaucher disease met its main targets in two late-stage studies, which the French drugmaker will use to bolster its case for regulatory approval.

Eliglustat tartrate could become the first oral treatment for Gaucher disease - a rare genetic disorder affecting some 10,000 patients - and shake up the market for therapies that currently have to be injected bi-weekly.

Eliglustat could generate annual sales of $360 million by 2017, according to ThomsonReuters Pharma forecasts.

Patients with Gaucher disease are deficient in an enzyme that breaks down a certain type of fat, leading to potentially life-threatening organ damage and bone problems.

The first study, presented at a medical congress on Friday, compared eliglustat with a placebo, while the second compared it with Cerezyme, an injectable treatment also sold by Sanofi.

Patients treated with the pill showed a "statistically significant improvement" in the size of their spleen - which typically swells as a result of Gaucher disease - without reporting serious side effects, Sanofi said.

Eliglustat also proved to be as good as Cerezyme at treating the symptoms of the disease, the drugmaker added.

Full data from the second trial will be presented at a medical meeting in the second half of 2013, Sanofi said in a statement.

A third late-stage study is currently testing whether the dosage for eliglustat could be reduced to once from twice daily.

In addition to Cerezyme, which for many years dominated the Gaucher market and was at one point the most expensive drug in the world, costing more than $200,000 a year, current treatments include Shire's Vpriv and Elelyso, sold by Pfizer.

(Reporting by Elena Berton; Editing by Christian Plumb and James Regan)

FILED UNDER:

Fighting Ebola

Reuters Showcase

Markets Weekahead

Markets Weekahead

Column - Caution advised in a trader’s market  Full Article 

Reuters Poll

Reuters Poll

RBI seen holding rates steady on Tuesday, minority of analysts expect cut  Full Article 

GDP Revised

GDP Revised

Economic growth revised up by almost 50 percent  Full Article 

Australian Open

Australian Open

Hingis wins Australian Open mixed doubles title with Paes   Full Article 

Houston's Daughter

Houston's Daughter

Bobbi Kristina Brown revived after found unresponsive in tub  Full Article 

India Art Fair

India Art Fair

Art fair turns India's capital into art hub.  Full Article 

Movie Review

Movie Review

"Rahasya" is an ode to Agatha Christie.  Full Article 

Review: Hawaizaada

Review: Hawaizaada

Movie Review: Hawaizaada  Full Article | Related Story 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage